Mixed data for Renovo's scarring therapy

Renovo's Juvista produced a mixed set of data in two mid-stage trials. The drug produced positive data in reducing scarring but failed to demonstrate efficacy during a breast augmentation trial. Researchers also said that the therapy was more effective against scarring when administered twice and noted that during the breast augmentation trial the drug was administered once. Renovo plans to launch a Phase III trial of Juvista in the second half of this year. Shire, a partner on the drug, agreed to invest $75 million in Juvista, plus make a $50 million equity investment in Renovo.

"Shire is at present assessing these latest results with all other results produced to date and plans to discuss these with the FDA in 2008 to determine the regulatory path forward in the United States," said Renovo in a statement.

- read the press release for more information

Related Articles:
Renovo inks $875M deal for scarring drug. Report
Renovo CEO bullish on partnership prospects. Report
Renovo sees shares jump on first day. Report

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.